In contrast, targeted protein degradation of SMARCA2/4, using the bromodomain-binding small molecule inhibitor to target PROTAC-driven degradation of the whole protein, robustly inhibits proliferation in numerous SMARCA2/4-dependent cancer cell lines [48]. The gene discussed is SMARCA2; the disease is cancer.